Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies

被引：21
作者：
Cao, Hanyu [1 ]
You, Di [1 ]
Lan, Zhu [2 ]
Ye, Hui [1 ]
Hou, Minmin [1 ,3 ]
Xi, Mingrong [1 ]
机构：
[1] Sichuan Univ, West China Univ Hosp 2, Dept Gynecol & Obstet, 20 Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China
[3] Univ Elect Sci & Technol China, Terahertz Sci & Technol Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China
来源：
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2018年 / 18卷 / 04期
基金：
美国国家科学基金会;
关键词：
Human epididymis protein 4; ovarian cancer; prognosis; survival; recurrence; EPIDIDYMIS PROTEIN 4; PREDICT OPTIMAL CYTOREDUCTION; NEWCASTLE-OTTAWA SCALE; DIAGNOSTIC PERFORMANCE; MALIGNANCY ALGORITHM; ROMA ALGORITHM; CA125; BIOMARKER; CHEMOTHERAPY; CA-125;
D O I：
10.1080/14737159.2018.1457436
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Introduction: Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. Accumulating evidence showed an evolving role of HE4 in monitoring the progression and prognosis of OC but without a comprehensive analysis for prognosis and survival data.Areas covered: The present meta-analysis aims to explore the association of HE4 with survival and the clinicopathological features of OC patients. PubMed, Embase, Web of Science and the China National Knowledge Infrastructure (CNKI) were searched for relevant studies regarding the role of both serum and tissue HE4 expression in ovarian cancer.Expert commentary: HE4 has been proposed as the most promising biomarker that may complement the CA125 expression and has been approved by the FDA in monitoring the follow-up and relapse of OC patients. Our results are in accordance with the most recent evidence suggesting its important role in the prognostic surveillance of OC and a better performance in the early prediction of OC recurrence than CA125.
引用
收藏
页码：371 / 383
页数：13
相关论文
共 123 条
[1]   HE4: a new potential early biomarker for the recurrence of ovarian cancer [J].
Anastasi, Emanuela ;
Marchei, Giulia Giovanna ;
Viggiani, Valentina ;
Gennarini, Giuseppina ;
Frati, Luigi ;
Reale, Maria Gabriella .
TUMOR BIOLOGY, 2010, 31 (02) :113-119
[2]   p53 Autoantibodies as Potential Detection and Prognostic Biomarkers in Serous Ovarian Cancer [J].
Anderson, Karen S. ;
Wong, Jessica ;
Vitonis, Allison ;
Crum, Christopher P. ;
Sluss, Patrick M. ;
LaBaer, Joshua ;
Cramer, Daniel .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (03) :859-868
[3]   Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? [J].
Angioli, Roberto ;
Capriglione, Stella ;
Aloisi, Alessia ;
Guzzo, Federica ;
Luvero, Daniela ;
Miranda, Andrea ;
Damiani, Patrizio ;
Montera, Roberto ;
Terranova, Corrado ;
Plotti, Francesco .
TUMOR BIOLOGY, 2014, 35 (07) :7009-7015
[4]   Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? [J].
Angioli, Roberto ;
Plotti, Francesco ;
Capriglione, Stella ;
Aloisi, Alessia ;
Montera, Roberto ;
Luvero, Daniela ;
Miranda, Andrea ;
Cafa, Ester Valentina ;
Damiani, Patrizio ;
Benedetti-Panici, Pierluigi .
GYNECOLOGIC ONCOLOGY, 2013, 128 (03) :579-583
[5]  
[Anonymous], CHINA CANC
[6]  
[Anonymous], MATERNAL CHILD HLTH
[7]  
Bai J, 2015, CHIN J OBSTET GYNECO, V4, P458
[8]   Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management [J].
Bandiera, Elisabetta ;
Romani, Chiara ;
Specchia, Claudia ;
Zanotti, Laura ;
Galli, Claudio ;
Ruggeri, Giuseppina ;
Tognon, Germana ;
Bignotti, Eliana ;
Tassi, Renata A. ;
Odicino, Franco ;
Caimi, Luigi ;
Sartori, Enrico ;
Santin, Alessandro D. ;
Pecorelli, Sergio ;
Ravaggi, Antonella .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (12) :2496-2506
[9]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[10]  
Bi YL, 2013, CHINA MED HERALD, V10, P58
12345678910